Market Notice 5/21– Last day of trading in Scandion Oncology A/S’s BTA
Scandion Oncology’s rights issue registered with the Danish Business Authority – BTAs are converted to sharesScandion Oncology A/S ("Scandion" or the "Company") has carried out a rights ...
Letter from the CEO: Great progress in 2020 - we are ready for 2021!Dear shareholder in Scandion Oncology, dear subscriber to Scandion Oncology N...
Scandion Oncology A/S – Flagging messageScandion Oncology A/S ("Scandion Oncology" or "the Company") hereby announces...
Scandion Oncology: Supplement to previously published press release regarding the outcome of Scandion Oncology’s rights issue
SCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUEScandion Oncology A/S ("Scandion" or the "Company") announces that the result...
Scandion Oncology publishes prospectus relating to the rights issue and announces the intention of changing listing venue to Nasdaq First North Growth Market SwedenThe Board of Directors of Scandion Oncology A/S ("Scandio...
Interim Report 1 January 2020 – 30 September 2020Scandion Oncology A/S ("Scandion Oncology" or "the Company") hereby...
Market Notice 283/20 – Information regarding the rights issue from Scandion Oncology A/S
Correction of previously published press release regarding Scandion Oncology’s rights issue (trading in BTAs)The press release of 16 November 2020 (released at 08:31:34) stated incorrect...
The Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 millionThe Board of Directors in Scandion Oncology A/S ("Scandion Oncology" or the "...
Correction: Scandion Oncology – Minutes of extraordinary general meetingErroneously the Press Release from 13 November, 2020 (released at 16:46:16) w...
Scandion Oncology – Minutes of extraordinary general meetingwhich was held on: Friday 13 November 2020, at 2.00 PM at Scandion Oncology...
Scandion Oncology: Notice to convene Extraordinary General Meeting in Scandion Oncology A/SScandion Oncology A/S (CVR-no. 38 61 33 91) (the "Company") Extraordinary ...
Scandion Oncology A/S initiates its second clinical study with SCO-101Scandion Oncology A/S is pleased to announce that its second clinical study w...
Scandion Oncology announces that the warrant exercise is registered at the Danish Companies Registration OfficeScandion Oncology A/S ("Scandion Oncology") today, October 9, 2020, announce ...
Scandion Oncology announces modified timelines for clinical studiesScandion Oncology A/S ("Scandion Oncology") today announces modified timeline...
Scandion Oncology receives approximately MSEK 12.3 through successful warrant exerciseOn Thursday, October 1, 2020, the exercise period for Scandion Oncology A/S (...
Scandion Oncology announces that it has been selected for the final round of MATWIN presentationsScandion Oncology A/S ("Scandion Oncology") today announces that the company ...
Communique from the Extraordinary General Meeting of Scandion Oncology A/SOn Thursday 1 October 2020, the Extraordinary General Meeting of Scandion Onc...
Scandion Oncology’s management and Board of Directors have exercised their Scandion Oncology A/S series TO 1 warrantsScandion Oncology announces that its management team and its Board of Directo...
Scandion Oncology receives final approval from the Danish Medicines Agency and Ethical Committee for start of a clinical trial in patients with pancreatic cancerScandion Oncology A/S ("Scandion Oncology") today announces that the company ...
Reminder to exercise Scandion Oncology A/S series TO 1 warrantsThe subscription period for the series TO 1 warrants issued as part of Scandi...
Market Notice 237/20 – Last day of trading in Scandion Oncology A/S:s subscription option SCOL TO 1
Notice to Extraordinary General Meeting in Scandion Oncology A/SThe Board of Directors of Scandion Oncology A/S ("Scandion Oncology" or the"C...
Scandion Oncology strengthens executive leadership appointing Bo Rode Hansen as CEO and Nils Brünner as new CSOScandion Oncology appoints Bo Rode Hansen as new President & CEO and co-f...
The exercise period for warrants in Scandion Oncology A/S begins todayToday, September 10th, 2020, marks the beginning of the exercise period for t...
Scandion Oncology announces results from the next evaluable chemo-resistant colorectal cancer patient treated with SCO-101 and chemotherapyScandion Oncology A/S ("Scandion Oncology") reports that the next evaluable c...
Half-Year Report 1 January 2020 – 30 June 2020Scandion Oncology A/S ("Scandion Oncology" or the "Company") hereby publishes...
Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 10% of the total share amountScandion Oncology A/S ("Scandion Oncology") announces that Saniona has reduce...
Scandion Oncology drug SCO-101 potentiates the effect of chemotherapy in the first cohort of patients with chemo-resistant metastatic colorectal cancerScandion Oncology A/S ("Scandion Oncology") reports on data from the first co...
Scandion Oncology announces that the results of the 4 SCO-101 clinical phase I trials have been published in the journal "Basic & Clinical Pharmacology & Toxocology".Scandion Oncology A/S ("Scandion Oncology") announces that the results from t...
Scandion Oncology announces that its Chairman of the Board has bought 6000 shares in Scandion OncologyScandion Oncology A/S ("Scandion Oncology") announces that its Chairman of th...
Scandion Oncology co-founders extend lock-up periodScandion Oncology A/S ("Scandion Oncology") announces that its two co-founder...
Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 15% of the total share amountScandion Oncology A/S ("Scandion Oncology") announces that Saniona has reduce...
Scandion Oncology has received a Eurostars grant of 800,000 EUR, shared with Erasmus Medical Centre, Rotterdam and 2cureX AB, for evaluating SCO-101 against antiestrogen resistance in breast cancerScandion Oncology A/S ("Scandion Oncology") is pleased to announce that it ha...
Scandion Oncology announces that the Clinical Trial Application for a pancreatic cancer study with chemotherapy and SCO-101 has been submitted to the Danish Medicines Agency and the Ethical Committee.Scandion Oncology A/S ("Scandion Oncology") is pleased to announce that a Cli...
Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncologyLund, Sweden, June 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) a...
Communique from the Annual General Meeting of Scandion Oncology A/SOn May 27th, 2020, the Annual General Meeting of Scandion Oncology A/S ("Scan...
Scandion Oncology announces that the first patient has received treatment with SCO-101 in combination with FOLFIRI.Scandion Oncology A/S ("Scandion Oncology") is pleased to announce that the f...
Interim report 1 January – 31 March 2020Scandion Oncology A/S ("Scandion Oncology" or "the Company") hereby publishes...
Scandion Oncology’s drug SOM-001 demonstrates antibiotic activity in a mouse model infected with MRSA bacteriaScandion Oncology has received positive results on the antibiotic in vivo eff...
Notice to Annual General Meeting in Scandion Oncology A/SThe Board of Directors of Scandion Oncology A/S ("Scandion Oncology" or the"C...
Scandion Oncology A/S Annual Report 2019 publishedScandion Oncology A/S ("Scandion Oncology") hereby publishes the Annual Repor...
Presentation of the ongoing Clinical Phase II trial at the AACR Virtual Annual MeetingOn April 27th CMO Peter Michael Vestlev will present at the AACR Virtual Annu...
Scandion Oncology CEO Newsletter (March 2020) Dear Scandion Oncology shareholder, Scandion Oncology wants to thank...
SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cellsScandion Oncology A/S ("Scandion Oncology") has published that combining SCO-...
Clinical development plans for SCO-101The current Phase II clinical study with SCO-101 is treating a serious diseas...
Short delay of the antibiotic resistance dataScandion Oncology A/S ("Scandion Oncology") hereby announces that the company...
Chairman, Vice-Chairman and CMO in Scandion Oncology A/S buy Company sharesScandion Oncology A/S ("Scandion Oncology" or "the Company") today announces ...
Short delay in the clinical phase II studyScandion Oncology A/S ("Scandion Oncology") informs about a short delay in th...
Publication on pre-clinical results with SCO-201Scandion Oncology A/S ("Scandion Oncology") hereby announces that the company...
Year-end Report 1 January - 31 December 2019Scandion Oncology A/S ("Scandion Oncology" or "the Company") hereby publishes...
Scandion Oncology receives DKK 5 million in soft money from Innovation Fund DenmarkScandion Oncology A/S ("Scandion Oncology") hereby announces that the company...
Correction of dates for public information on Estimated Primary Completion and Primary Study Completion for a Clinical Phase II studyThe clinical Phase II trial with drug resistant metastatic colorectal cancer ...
Scandion Oncology Newsletter 27 January, 2020
Scandion Oncology Newsletter 21st January, 2020CEO Nils Brünner and Chairman of the Board Peter Høngaard, have now safely re...
Scandion Oncology News, January 2020
Scandion Oncology to attend the JP Morgan 38th Annual Healthcare ConferenceScandion Oncology A/S ("Scandion Oncology") Chief Executive Officer Nils Brün...
Peter Høngaard interviewed by Bio StockBio Stock has interviewed the Peter Høngaard, Chairman of the Board, about th...
Scandion Oncology obtains approval from the Ethics Committee on Clinical Application for SCO-101 in patients with drug-resistant metastatic colorectal cancerScandion Oncology A/S ("Scandion Oncology") today announces that the company ...
Anti-bacterial treatment: Novel analogues with more than tenfold higher potency identified and technical issues with the in vivo experimentsScandion Oncology A/S (“Scandion Oncology”) today announces that ...
Chairman and Vice-Chairman of the Board in Scandion Oncology A/S buy Company sharesScandion Oncology A/S ("Scandion Oncology" or "the Company") today announces ...
Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancerScandion Oncology A/S (“Scandion Oncology”) today announces that ...
Scandion Oncology CEO Newsletter November 2019Dear Scandion Oncology shareholder,Being able to change drug resistance will ...
Interim Report 1 January 2019 - 30 September 2019Scandion Oncology A/S (”Scandion Oncology” or the “Company&...
Scandion Oncology A/S receives EU-patent for SCO-101Scandion Oncology A/S (“Scandion Oncology”) today announces that ...
Scandion Oncology applies for start of clinical Phase II trial in patients with metastatic colorectal cancerScandion Oncology A/S (“Scandion Oncology”) today announces that ...
In vivo animal data report on antibiotic resistance extended until mid-Q4 2019Scandion Oncology A/S (“Scandion Oncology”) today announces that ...
Peter Høngaard new Chairman of the Board in Scandion OncologyScandion Oncology A/S (“Scandion Oncology”) today announces that ...
Scandion Oncology CEO Newsletter autumn 2019Dear Scandion Oncology shareholder, Scandion Oncology is heading towards an ...
Flagging notification in Scandion Oncology A/SScandion Oncology A/S (”Scandion Oncology”) hereby announces that, in connect...
Half-Year Report 1 January 2019 - 30 June 2019Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes...
Update on Q & AScandion Oncology wishes to make aware that we have published a new Q&A on Au...
First day of trading in TO 1 in Scandion OncologyIn June/July 2019, Scandion Oncology A/S (“Scandion Oncology”) conducted a ri...
Market Notice 210/19 - Last day of trading in Scandion Oncology A/S"s BTU
Last day of trading in BTU in Scandion OncologyIn June/July 2019, Scandion Oncology A/S (“Scandion Oncology”) conducted a ri...
Significantly oversubscribed rights issue in Scandion OncologyOn July 9, 2019, the subscription period in Scandion Oncology A/S’s ("Scandio...
Scandion Oncology has identified four clinical sites to take part in the planned Phase II clinical trialScandion Oncology A/S (“Scandion Oncology” or the “Company”) today announces ...
SCO-101 is successfully produced as tabletsScandion Oncology A/S (”Scandion”) today announced that SCO-101 tablets have ...
The subscription period in Scandion Oncology"s rights issue begins todayToday, on the 20th of June, 2019, the subscription period for Scandion Oncolo...
Scandion Oncology A/S publishes prospectus in connection with rights issueProspectus relating to the rights issue in Scandion Oncology A/S (”Scandion O...
Market Notice 159/19 - Update - Information regarding the rights issue from Scandion Oncology A/S
Market Notice 152/19 - Information regarding the rights issue from Scandion Oncology A/S
Communique from the Extraordinary General Meeting in Scandion Oncology A/SOn June 11th, 2019, the Extraordinary General Meeting of Scandion Oncology A/...
Scandion Oncology appoints Chairman and Vice-Chairman of its Board of DirectorsScandion Oncology A/S (“Scandion Oncology”) hereby announces that Jørgen Bard...
Main shareholders signs lock-up agreements for 12 monthsIn connection with the announcement that the Board of Directors of Scandion O...
Communique from the Annual General Meeting of Scandion Oncology A/SOn May 29th, 2019, the Annual General Meeting of Scandion Oncology A/S (”Scan...
Notice of Extraordinary General Meeting in Scandion Oncology A/SThe Board of Directors of Scandion Oncology A/S (”Scandion Oncology” or the “...
The board of Scandion Oncology proposes a rights issue to increase the commercial potential for its drug candidates and to expand its drug pipelineScandion Oncology A/S (“Scandion Oncology” or ”the Company”) today announces ...
Interim report 1 January - 31 March 2019Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes...
Scandion Oncology A/S announces new date for publication of interim report January - March 2019Scandion Oncology A/S would like to make use of the full window for releasing...
SCANDION ONCOLOGY A/S obtains "Intention to Grant" notice for SCO-101 from the European Patent Office (EPO)SCANDION ONCOLOGY A/S is pleased to announce that the company has received an...
Notice to Annual General Meeting in Scandion Oncology A/SThe Board of Directors of Scandion Oncology A/S (”Scandion Oncology” or the“C...
Scandion Oncology A/S Annual Report 2018 publishedScandion Oncology A/S hereby publishes the Annual Report for 2018. The Annual...
Scandion Oncology signs collaboration agreement with University of Copenhagen regarding co-development of a class of drug candidates that reverts anti-cancer drug resistanceScandion Oncology A/S (”Scandion” or ”the Company”) announces today that the ...
Scandion Oncology obtains EU Funding for SCO-101 in drug resistant breast cancer patientsScandion Oncology A/S (”Scandion” or ”the Company”) announces today that the ...
Scandion Oncology A/S reports successful meeting with Danish Medicines Agency regarding clinical development of SCO-101 Scandion Oncology and The Danish Medicines Agency have had a very positive ...
Scandion Oncology Signs Contract with Solural Pharma to Formulate SCO-101 Tablets for Clinical Phase II Trial Scandion Oncology A/S and Solural Pharma ApS have entered into an agreement...
Scandion Oncology A/S Obtains Positive Preclinical Results in Antibiotic ResistanceScandion Oncology A/S (Scandion Oncology) hereby announces that Scandion Onco...
Presentation video in relation to year-end reportScandion Oncology has made two videos to present the company and the basic co...
Year End Report for 2018Scandion Oncology has published the Year End Report for 2018. The Press Relea...
Year-end Report 1 January - 31 December 2018Scandion Oncology A/S (”Scandion Oncology” or ”the Company”) hereby publishes...
Senior executives increase their holdings in Scandion OncologyThe increase of shares of senior executives in Scandion Oncology can be viewe...
Disclosure notice
Senior executives increase their holdings in Scandion Oncology A/SScandion Oncology A/S ("Scandion Oncology") today announces that the Chairman...
Scandion Oncology informs on the selection of collaborator for the Boost4Health Internationalisation grantScandion Oncology A/S (“Scandion Oncology”) today announces that the company ...
Interim Report Q3 2018Scandion Oncology A/S (”Scandion Oncology”) herby reports interim report for ...
Scandion Oncology to receive EU support to boost international developmentScandion Oncology A/S has been granted an Impact Voucher of 14.999 EUR from B...
First day of trading in Scandion Oncology A/S shares on Spotlight Stock MarketToday, November 8, 2018, is the first day of trading in Scandion Oncology A/S...
Marknadsmeddelande 260/18- Scandion Oncology A/S noteras på Spotlight Stock Market den 8 november2018Första handelsdag på Spotlight Stock Market för Scandion Oncology A/S aktie ä...
Scandion Oncology A/S new share issue oversubscribedOn October 18, 2018, the subscription period for Scandion Oncology A/S’s ("Sc...
Idag inleds teckningstiden i Scandion Oncology A/S nyemission inför planerad notering på Spotlight Stock MarketIdag, den 4 oktober 2018, inleds teckningstiden i Scandion Oncology A/S ("Sca...
The subscription period for Scandion Oncology A/S new share issue begins todayToday, October 4, 2018, the subscription period for Scandion Oncology A/S ("S...
Scandion Oncology A/S approved for listing at Spotlight Stock MarketToday, Scandion Oncology A/S (“Scandion Oncology”) announces that the company...
Scandion Oncology A/S är godkänt för notering på Spotlight Stock MarketScandion Oncology A/S (“Scandion Oncology”) meddelar idag, den 1 oktober 2018...
Scandion Oncology A/S signs agreement with Sedermera Fondkommission AB regarding an Initial Public Offering at Spotlight Stock Market.Scandion Oncology A/S hereby announces that an agreement has been signed w...
Scandion Oncology A/S hereby announces that an agreement has been signed w...
Saniona Spin-Out, Scandion Oncology Raises DKK 2 Million and Prepares for a Potential Public ListingSaniona, a leading biotech company in the field of ion channels, today announ...
New Saniona spinout focused on cancer therapyScandion Oncology, a spinout from the biotech company Saniona, offers experie...
Saniona satser på spinout-virksomhederDet danske biotekselskab Saniona har netop etableret sin tredje spinout-virks...
Nyt Saniona-spinout har fokus på kræftScandion Oncology, der er en spinout-virksomhed fra biotekselskabet Saniona, ...